mTOR inhibitors in cancer therapy [version 1; referees: 3 approved]

Jianling Xie, Xuemin Wang, Christopher G. Proud

Research output: Contribution to journalReview articlepeer-review

205 Citations (Scopus)
41 Downloads (Pure)


The mammalian target of rapamycin, mTOR, plays key roles in cell growth and proliferation, acting at the catalytic subunit of two protein kinase complexes: mTOR complexes 1 and 2 (mTORC1/2). mTORC1 signaling is switched on by several oncogenic signaling pathways and is accordingly hyperactive in the majority of cancers. Inhibiting mTORC1 signaling has therefore attracted great attention as an anti-cancer therapy. However, progress in using inhibitors of mTOR signaling as therapeutic agents in oncology has been limited by a number of factors, including the fact that the classic mTOR inhibitor, rapamycin, inhibits only some of the effects of mTOR; the existence of several feedback loops; and the crucial importance of mTOR in normal physiology.

Original languageEnglish
Article number2078
Number of pages11
Publication statusPublished - 2016
Externally publishedYes


  • mTor
  • Cancer Therapy
  • Inhibitors


Dive into the research topics of 'mTOR inhibitors in cancer therapy [version 1; referees: 3 approved]'. Together they form a unique fingerprint.

Cite this